Biotech Business - November 15, 2023
Gedea Biotech raises EUR 1.5 million
Gedea Biotech has raised the financing to initiate and accelerate clinical trial activities supporting pHyph applicable for antibiotic free treatment of vaginal infections. The funds will be used to initiate patient recruitment in the recently approved registration CL3-2-study, reach upcoming data readout from the CL4 -study to obtain pHyph proof-of-concept for treating vaginal fungal infections, […]
Biotech Business - November 15, 2023
Neogap Therapeutics raises SEK 83 million
The company has raised SEK 54 million in a new share issue and has also been granted an additional SEK 29 million in innovation funding from the EU. The company has strengthened its financial position through a new share issue, with the investment company Sciety and investment syndicate Sciety Venture Partners. Alongside this, the company […]
Financing - November 13, 2023
BICO has divested Ginolis
BICO has divested Ginolis through a management buy-out to Ginolis’ current CEO Kauko Väinämö. The purchase price amounted to USD 1. The transaction is estimated to result in a divestment loss of SEK -25 million, which is a non-cash item. Final divestment result will be reported and disclosed in the Q4 report, states the company. […]
Collaboration - November 8, 2023
FinnGen’s next chapter
The Finnish Genomics initiative FinnGen has entered its next phase, backed by EUR 52 million of new funding. Since its initiation in 2017, FinnGen has developed into one of the world’s leading biobank-based genomic research projects. It has completed the construction of a research resource that integrates genomic information from half a million Finnish biobank […]
Biotech Business - November 8, 2023
Modus Therapeutics raises SEK 40.3 million
The Board of Directors of Modus Therapeutics Holding has resolved to carry out a new issue of up to 20,125,060 shares with pre-emptive rights for the company’s shareholders, as well as a directed issue of 10,156,569 shares through the offsetting of loans from Karolinska Development AB amounting to approximately SEK 20.3 million. The Rights Issue […]
Biotech Business - November 8, 2023
Medivir raises approximately SEK 148 million
The Board of Directors of Medivir has resolved to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 148 million. An extraordinary general meeting is proposed to approve the Board of Directors’ resolution on the Rights Issue. The EGM is set to be held on 1 December 2023. […]
